Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.31 (
beta-glucuronidase
)
7,680
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
(1) The effect of feeding a relatively low-protein diet containing 0.06% DAB for 29 weeks on the activity of DAB-azoreductase, nitroreductase (p-nitrobenzoic acid), N-oxidase (
N,N-dimethylaniline
), N-demethylase (DAB), cytochrome P-450, NADPH-cytochrome c reductase,
beta-glucuronidase
and arylsulphatase A were studied. Rapid decreases occurred in the activities of the first six enzymes, reaching minimal values at between 4 and 8 weeks. Activities then increased in all cases to control or nearly control levels. This rate of increase was least for cytochrome P-450. At 4 weeks azoreductase activity with the chemotherapeutic agent CB10-252 (I) as substrate was significantly higher than in control rats. Early increases occurred in the activities of
beta-glucuronidase
and arylsulphatase A and the activity of the latter never dropped below the control level. (2) An investigation was made of the differential effects of dye feeding on some of the enzyme activities in the two major liver lobes and differences were found. (3) The effect of phenobarbital (PB) pretreatment on the DAB-fed rats was studied at 4-week intervals. The activities of DAB-azoreductase and of nitroreductase increased throughout the whole period, while the activities of the lysosomal enzymes were decreased. (4) After feeding DAB for 4 weeks the effect of PB and 3-methylcholanthrene (MC) on the activities of DAB-azoreductase, CB10-252-azoreductase and components of the azoreductases-cytochrome P-450, NADPH-cytochrome c reductase, the CO-CB10-252-azoreductase was not induced by PB or MC, and CO did not inhibit its reduction. Its reduction depended only slightly on NADH. CO caused a greater relative decrease in the activity of DAB-azoreductase in dye-fed animals and also in animals following PB and MC pretreatment, implying a greater role of cytochrome P-450 in dye-fed animals.
...
PMID:The effects of the continuous administration of N,N-dimethyl-4-phenylazoaniline (DAB) on the activities and the inducibilities of some drug-metabolizing enzymes in rat liver. 0 Jan 48
1. Incubation of
N,N-dimethylaniline
(DMA) with isolated rat hepatocytes resulted in the production of N-methylaniline, aniline,
N,N-dimethylaniline
N-oxide (DMA N-Oxide) and a highly water-soluble metabolic tentatively identified as N-methylaniline N-glucuronide. 2. After the removal of aniline, N-methylaniline and DMA, treatment of the media with either strong acid or
beta-glucuronidase
, resulted in the release of N-methylaniline, identified by chromatography and mass spectrometry. 3. Pre-incubation of rat hepatocytes with 2 mM D-galactosamine, which decreased 7-hydroxycoumarin conjugate formation by 40%, selectively decreased the formation of this highly water-soluble metabolite from DMA by 70%. DMA N-demethylase and N-oxidase activities remained unchanged. 4. Incubation of rat hepatocytes with N-methylaniline resulted in the production of the novel metabolite, the formation of which was proportional to cell number, incubation time, and N-methylaniline (substrate) concentration. 5. The N-glucuronidation of the secondary N-alkylarylamine, N-methylaniline, by rat hepatocytes represents a quantitatively important and previously uncharacterized route of metabolism in these cells. Further studies are, however, required to identify this metabolite unequivocally as the N-glucuronide of N-methylaniline.
...
PMID:The metabolism of N,N-dimethylaniline by isolated rat hepatocytes: identification of a novel N-conjugate. 275 Feb 2